Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE".
dc.contributor.author | Schöffski, P | |
dc.contributor.author | Wozniak, A | |
dc.contributor.author | Casali, P | |
dc.contributor.author | Rutkowski, P | |
dc.contributor.author | Blay, J | |
dc.contributor.author | Lindner, L | |
dc.contributor.author | Strauss, S | |
dc.contributor.author | Anthoney, A | |
dc.contributor.author | Duffaud, F | |
dc.contributor.author | Richter, S | |
dc.contributor.author | Grünwald, V | |
dc.contributor.author | Leahy, Michael G | |
dc.contributor.author | Reichardt, P | |
dc.contributor.author | Sufliarsky, J | |
dc.contributor.author | van der Graaf, W | |
dc.contributor.author | Sciot, R | |
dc.contributor.author | Debiec-Rychter, M | |
dc.contributor.author | van Cann, T | |
dc.contributor.author | Marréaud, S | |
dc.contributor.author | Lia, M | |
dc.contributor.author | Raveloarivahy, T | |
dc.contributor.author | Collette, L | |
dc.contributor.author | Bauer, S | |
dc.date.accessioned | 2017-10-23T19:35:59Z | |
dc.date.available | 2017-10-23T19:35:59Z | |
dc.date.issued | 2017-09-18 | |
dc.identifier.citation | Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". 2017, Ann Oncol | en |
dc.identifier.issn | 1569-8041 | |
dc.identifier.pmid | 28950372 | |
dc.identifier.doi | 10.1093/annonc/mdx527 | |
dc.identifier.uri | http://hdl.handle.net/10541/620617 | |
dc.description.abstract | Clear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology | en |
dc.title | Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". | en |
dc.type | Article | en |
dc.contributor.department | Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium | en |
dc.identifier.journal | Annals of Oncology | en |
refterms.dateFOA | 2020-04-03T11:41:38Z | |
html.description.abstract | Clear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA. |